Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 多克隆抗體
  4. SOX17 Antibody
  • 中文名稱：
    SOX17兔多克隆抗體
  • 貨號：
    CSB-PA887989LA01HU
  • 規(guī)格：
    ￥440
  • 促銷：
    小規(guī)格抗體限時一口價
  • 圖片：
    • Immunohistochemistry of paraffin-embedded human glioma using CSB-PA887989LA01HU at dilution of 1:100
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品名稱：
    Rabbit anti-Homo sapiens (Human) SOX17 Polyclonal antibody
  • Uniprot No.：
  • 基因名：
  • 別名：
    FLJ22252 antibody; SOX17 antibody; SOX17_HUMAN antibody; SRY (sex determining region Y) box 17 antibody; SRY box 17 antibody; SRY related HMG box transcription factor SOX17 antibody; Transcription factor SOX-17 antibody; Transcription factor SOX17 antibody; VUR3 antibody
  • 宿主：
    Rabbit
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human Transcription factor SOX-17 protein (177-414AA)
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated

    本頁面中的產(chǎn)品，SOX17 Antibody (CSB-PA887989LA01HU)，的標(biāo)記方式是Non-conjugated。對于SOX17 Antibody，我們還提供其他標(biāo)記。見下表：

    可提供標(biāo)記
    標(biāo)記方式 貨號 產(chǎn)品名稱 應(yīng)用
    HRP CSB-PA887989LB01HU SOX17 Antibody, HRP conjugated ELISA
    FITC CSB-PA887989LC01HU SOX17 Antibody, FITC conjugated
    Biotin CSB-PA887989LD01HU SOX17 Antibody, Biotin conjugated ELISA
  • 克隆類型：
    Polyclonal
  • 抗體亞型：
    IgG
  • 純化方式：
    >95%, Protein G purified
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用范圍：
    ELISA, IHC
  • 推薦稀釋比：
    Application Recommended Dilution
    IHC 1:20-1:200
  • Protocols：
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評價

靶點詳情

  • 功能：
    Acts as transcription regulator that binds target promoter DNA and bends the DNA. Binds to the sequences 5'-AACAAT-'3 or 5'-AACAAAG-3'. Modulates transcriptional regulation via WNT3A. Inhibits Wnt signaling. Promotes degradation of activated CTNNB1. Plays a key role in the regulation of embryonic development. Required for normal development of the definitive gut endoderm. Required for normal looping of the embryonic heart tube. Plays an important role in embryonic and postnatal vascular development, including development of arteries. Plays an important role in postnatal angiogenesis, where it is functionally redundant with SOX18. Required for the generation and maintenance of fetal hematopoietic stem cells, and for fetal hematopoiesis. Probable transcriptional activator in the premeiotic germ cells.
  • 基因功能參考文獻(xiàn)：
    1. Case-control analyses reveal significant overrepresentation of rare variants in ATP13A3, AQP1 and SOX17, and provide independent validation of a critical role for GDF2 in heritable pulmonary arterial hypertension. PMID: 29650961
    2. These data strongly implicate SOX17 as a new risk gene contributing to Pulmonary arterial hypertension-congenital heart disease. PMID: 30029678
    3. This study showed that 1 of 4 SNPs located near the SOX17 gene, rs1072737, was statistically associated with intracranial aneurysm (IA) formation in a Korean population. The MAF of this variant (minor allele, C) showed a highly ethnic difference between Korean and European populations. Two SNPs rs10958409 and rs9298506 showed statistically significant associations with increased IA risk in the current meta-analysis. PMID: 29191544
    4. The combination of methylated SOX17 with cytology better predicted neoplastic grade than cytology alone PMID: 28148542
    5. SOX17 acts as a tumor suppressor in cholangiocarcinoma and its genetic, molecular and/or pharmacological restoration may represent a new promising therapeutic strategy. PMID: 28237397
    6. Our results suggest that decreasing SOX17 levels may promote EC development and progression, and that by downregulating MAML3 expression and Wnt signaling, SOX17 acts as a tumor suppressor that may improve outcome in patients with EC. PMID: 27738313
    7. SOX2 repression in TCam-2 cells can be abrogated by recruitment of the constitutively expressed H3K27 demethylase UTX to the SOX2 promoter through retinoid signaling, leading to expression of neuronal and other lineage genes. SOX17 has been shown to initiate human PGC specification, with its target PRDM1 suppressing mesendodermal genes PMID: 27132888
    8. Dedifferentiation of fibroblasts to CD34(+) progenitor cells gives rise to endothelial cells and erythroblasts in a SOX17-dependent manner. PMID: 28381471
    9. Study extracted and analyzed the experimentally validated 3D models of SOX17-HMG domain and beta-catenin; the molecular level disturbance in the two essential human proteins upon M76A and G103R mutation of SOX17, which further hampers the cell signaling phenomena for the human cytological developments beginning from gastrulation and endoderm formation. PMID: 28132771
    10. SOX17 promoter is highly methylated in primary tumors and in corresponding plasma samples both in operable and advanced non-small cell lung cancer. PMID: 26741346
    11. The definitive endoderm and foregut endoderm differentiation capabilities of Wnt pathway-modulated cells were determined based on the expression levels of the endodermal transcription factors SOX17 and FOXA2 and those of the transcription activator GATA4 and the alpha-fetoprotein (AFP) gene, respectively. PMID: 26861571
    12. Knockdown of OCT4 during differentiation inhibits mesendoderm formation and removal of the H3K27me3 mark from the SOX17 promoter, suggesting that OCT4 acts to induce removal of the Polycomb2 complex. PMID: 26411902
    13. high expression of the Sox17 associated pathway in medium and small arteries indicates that Brain arteriovenous malformation vessels are intrinsically active PMID: 26463399
    14. SOX17 demethylation induced miR-371-5p expression and consequently suppressed its direct target SOX2. A novel mechanism of the SOX17/miR-371-5p/SOX2 axis is involved in the regulation of EMT, stemness and metastasis. PMID: 25868860
    15. Decreased expression of SOX17 is associated with tumor progression in breast cancer. PMID: 25971583
    16. In this study, oligodendroglioma patients with 1p/19q LOH and Sox17 protein expression had a better prognosis. PMID: 25674225
    17. SOX17 might play a role in the development of Ovarian Cancer, and may be a therapeutic target in OC. PMID: 25953442
    18. Decreased Sox17 expression is correlated with melanoma progression, an unfavorable survival of melanoma patients and is an independent molecular prognostic factor for melanoma. PMID: 25310020
    19. Possible association of SOX-17 and RBBP8 with brain arteriovenous malformations, genes involved in cell cycle progression, deserves further investigation PMID: 25053769
    20. promoter methylation may play an important role in breast cancer progression and could be used as a prognostic biomarker to identify patients at risk of developing metastasis or recurrence after mastectomy PMID: 25789956
    21. Human intracranial aneurysm samples showed reduced Sox17 expression and impaired endothelial integrity. PMID: 25596186
    22. Low Sox17 expression is associated with hepatocellular carcinoma. PMID: 25106407
    23. SOX17 is the key regulator of human primordial germ cells-like cells specification, whereas BLIMP1 represses endodermal and other somatic genes during hPGCLC specification. PMID: 25543152
    24. Hypermethylation of SOX17 promoter may be one of the early events in the development of myelodysplatic syndrome and predicts poor prognosis. PMID: 25291942
    25. Low SOX17 expression is associated with esophageal cancer progression. PMID: 24407731
    26. Experimental confirmation of miRNA-mRNA interactions established a critical role of miR-200a in regulating both EMT and definitive endoderm formation, through direct repression of ZEB2 and SOX17, during early stage differentiation. PMID: 23813959
    27. In multiple sclerosis tissue, Sox17 was primarily detected in actively demyelinating lesions and periplaque white matter. PMID: 23918253
    28. Immunofluorescence analysis of human pancreatic tissue arrays revealed the presence of tuft cells in metaplasia and early-stage tumors, along with SOX17 expression, consistent with a biliary phenotype. PMID: 23999170
    29. Overall survival of patients with gastric cancer was found to be significantly associated with SOX17 promoter methylation. PMID: 23403728
    30. after electrostatic interactions attract Sox17 to DNA, Asn73, Ser99, and Trp106 form hydrogen bonds with DNA, Arg70, Lys80, Arg83, His94, and Asn95 on Sox17 undergo conformational changes and form hydrogen bonds with DNA PMID: 23061670
    31. recombinant Sox17 mediates modulation of the Wnt pathway through changes in beta-catenin, SFRP1 and Wnt/Frizzled expression. PMID: 23474492
    32. SOX17 promoter is highly methylated in primary breast tumors, in CTCs isolated from patients with breast cancer, and in corresponding cfDNA samples PMID: 23136251
    33. SOX17 plays a key role in priming hemogenic potential in endothelial cells, thereby regulating hematopoietic development from stem cells. PMID: 23169777
    34. SOX17 acts as a Wnt signaling inhibitor. PMID: 22846201
    35. findings establish Sox17 as a key regulator of tumor angiogenesis and tumor progression. PMID: 23241958
    36. SOX17 was frequently methylated in human PTC. Loss of SOX17 expression was induced by promoter region hypermethylation. SOX17 inhibited thyroid cancer proliferation. Methylation of SOX17 activated the Wnt signaling pathway in human thyroid cancer. PMID: 23044318
    37. SOX17 promoter region is frequently methylated in esophageal cancer and in a progression tendency during esophageal carcinogenesis. PMID: 22921431
    38. provided further evidence to support the previously reported association of intracranial aneurysm with single nucleotide polymorphism in SOX17 PMID: 22961961
    39. New sequence variations in SOX17 were identified but all correspond to nonpathogenic variants, suggesting that SOX17 is not involved in UHL phenotype PMID: 22348788
    40. silencing of Sox17 occurs frequently in early gastric cancer PMID: 22161215
    41. Downstream targets of Sox17 define signaling pathways and molecular mechanisms in oligodendrocyte progenitor cells that are regulated by Sox17 during cell cycle exit and differentiation in oligodendrocyte development. PMID: 21957254
    42. A stage-specific transduction of SOX17 in the primitive endoderm or mesendoderm promotes directive extraembryonic endoderm or definitive endoderm differentiation by SOX17 transduction, respectively. PMID: 21760905
    43. Sox17 might be a key transcription factor controlling CD133 expression, and that it might also play a role in the control of gastric tumor progression. PMID: 21457403
    44. SOX17(+)-human embryonic stem cell progeny expressed endodermal markers. PMID: 21362573
    45. Data show that down-regulated by Sox17 expressing HepG2 cells is a set of genes that are expressed in the developing liver, suggesting that one function of Sox17 is the repression of liver gene expression. PMID: 21305474
    46. Sox17 prominently contributes to gastric cancer progression through regulating proliferation and cell cycle, indicating a novel diagnosis and prognosis biomarker as well as a potential therapeutic target in gastric cancer PMID: 21514720
    47. SOX17 negatively regulates canonical WNT/beta-catenin signaling pathway and inhibits human HCC cells growth PMID: 20716954
    48. These data indicate a role of SOX17 in human kidney and urinary tract development and implicate the SOX17-p.Y259N mutation as a causative factor in congenital anomalies of the kidney and the urinary tract . PMID: 20960469
    49. Sox17 may be a valuable biomarker for the study of breast cancer carcinogenesis and progression. PMID: 19301122
    50. SOX17 silencing due to promoter hypermethylation is an early event during tumorigenesis and may contribute to aberrant activation of Wnt signaling in colorectal cancer. PMID: 18413743

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Vesicoureteral reflux 3 (VUR3)
  • 亞細(xì)胞定位：
    Nucleus.
  • 組織特異性：
    Expressed in adult heart, lung, spleen, testis, ovary, placenta, fetal lung, and kidney. In normal gastrointestinal tract, it is preferentially expressed in esophagus, stomach and small intestine than in colon and rectum.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 18122

    OMIM: 610928

    KEGG: hsa:64321

    STRING: 9606.ENSP00000297316

    UniGene: Hs.98367